BRAF Mutations in Thyroid Cancer

Marcia S. Brose, MD, PhD, Abramson Cancer Center, University of Pennsylvania, discusses BRAF mutations in thyroid cancer.a

Clinical Pearls

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discussesBRAFmutations in thyroid cancer.

  • The BRAF pathway is a good target, though predictive nature depends largely on the agent
  • Both the BRAF and MAPK pathways are extremely dynamic
  • MAPK is an important pathway, regardless of upregulation of the BRAF wild type pathway